Delivery Order SPE2DB24D3013-SPE2DB25FFNMZ
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.52 for ORGOVYX 120 mg tablets (30-unit package) on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit of use packaging) with a firm fixed price structure. The order was competitively awarded without set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location in the same city. This delivery order is...
- The Defense Logistics Agency awarded a $4,156.56 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the federal government's medical...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,375.85, is a delivery order for ORGOVYX 120 MG TABLET medical supplies. The contract has an ultimate completion date of December 11, 2024 and is a firm fixed-price type. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of ORGOVYX 120 MG TABLET UU 30S. This $7,979.34 order has a completion date of March 11, 2024 and does not utilize any set-aside designation. Amerisourcebergen Drug Corp is the prime contractor and holds a broader indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00 to deliver pharmaceutical...
- This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,156.56, is a delivery order for ORGOVYX 120 MG TABLET with an ultimate completion date of April 22, 2025. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of ORGOVYX 120 mg tablets. The contract has a potential value of $1,329.89 and a completion date of March 1, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor on this contract to supply pharmaceuticals and medical supplies to support military treatment...
- The U.S. Defense Logistics Agency (DLA) awarded a $8,313.12 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is to deliver ORGOVYX 120 MG TABLET UU 30S, a pharmaceutical product, with a completion date of February 10, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a...
- This is a $1,385.52 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ORGOVYX 120 MG TABLET, with a completion date of July 29, 2025. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply ORGOVYX 120 MG TABLET pharmaceuticals. The $7,979.34 contract has a performance period ending on March 28, 2024. Amerisourcebergen Drug Corp serves as the prime contractor for this delivery order, which is issued under a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00 with DLA Troop Support...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFNMZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit of use packaging) with a firm fixed price and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order represents a pharmaceutical supply transaction to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, leveraging its extensive federal contract portfolio to fulfill diverse medical supply requirements across the Defense Health Agency and related military healthcare programs. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. The company's performance under this contract vehicle demonstrates its capability to meet federal procurement requirements through open competition and positions it among potential contractors for DLA's planned Pharmaceutical Prime Vendor Global Program Generation V contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 7/21/25 |